Last reviewed · How we verify
Tenofovir + emtricitabine + lopinavir/ritonavir
Tenofovir + emtricitabine + lopinavir/ritonavir is a Antiretroviral combination (NRTI + protease inhibitor) Small molecule drug developed by Juan A. Arnaiz. It is currently FDA-approved for HIV-1 infection.
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication.
This combination inhibits HIV reverse transcriptase and protease to suppress viral replication. Used for HIV-1 infection.
At a glance
| Generic name | Tenofovir + emtricitabine + lopinavir/ritonavir |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination (NRTI + protease inhibitor) |
| Target | HIV reverse transcriptase, HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Tenofovir and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral RNA conversion to DNA. Lopinavir/ritonavir is a protease inhibitor combination where ritonavir boosts lopinavir levels by inhibiting its metabolism, allowing lopinavir to block HIV protease and prevent viral maturation. Together, they suppress HIV replication at multiple stages.
Approved indications
- HIV-1 infection
Common side effects
- Diarrhea
- Nausea
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Lipodystrophy
- Hepatotoxicity
- Renal dysfunction (tenofovir-related)
- Lactic acidosis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (NA)
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir + emtricitabine + lopinavir/ritonavir CI brief — competitive landscape report
- Tenofovir + emtricitabine + lopinavir/ritonavir updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI
Frequently asked questions about Tenofovir + emtricitabine + lopinavir/ritonavir
What is Tenofovir + emtricitabine + lopinavir/ritonavir?
How does Tenofovir + emtricitabine + lopinavir/ritonavir work?
What is Tenofovir + emtricitabine + lopinavir/ritonavir used for?
Who makes Tenofovir + emtricitabine + lopinavir/ritonavir?
What drug class is Tenofovir + emtricitabine + lopinavir/ritonavir in?
What development phase is Tenofovir + emtricitabine + lopinavir/ritonavir in?
What are the side effects of Tenofovir + emtricitabine + lopinavir/ritonavir?
What does Tenofovir + emtricitabine + lopinavir/ritonavir target?
Related
- Drug class: All Antiretroviral combination (NRTI + protease inhibitor) drugs
- Target: All drugs targeting HIV reverse transcriptase, HIV protease
- Manufacturer: Juan A. Arnaiz — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection
- Compare: Tenofovir + emtricitabine + lopinavir/ritonavir vs similar drugs
- Pricing: Tenofovir + emtricitabine + lopinavir/ritonavir cost, discount & access